Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study.
Identifieur interne : 002D30 ( PubMed/Checkpoint ); précédent : 002D29; suivant : 002D31Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study.
Auteurs : Isaac Shpirer [Israël] ; Ala Miniovitz ; Colin Klein ; Richard Goldstein ; Tatiana Prokhorov ; Jack Theitler ; Lea Pollak ; Jose Martin RabeySource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antiparkinson Agents (therapeutic use), Benzodiazepines (therapeutic use), Clonazepam (therapeutic use), Cohort Studies, Comorbidity, Disorders of Excessive Somnolence (diagnosis), Disorders of Excessive Somnolence (drug therapy), Disorders of Excessive Somnolence (epidemiology), Dopamine Agonists (therapeutic use), Drug Therapy, Combination, Female, Humans, Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Polysomnography, Reference Values, Restless Legs Syndrome (diagnosis), Restless Legs Syndrome (drug therapy), Restless Legs Syndrome (epidemiology), Sleep Stages (drug effects), Wakefulness (drug effects).
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Benzodiazepines, Clonazepam, Dopamine Agonists, Levodopa.
- diagnosis : Disorders of Excessive Somnolence, Parkinson Disease, Restless Legs Syndrome.
- drug effects : Sleep Stages, Wakefulness.
- drug therapy : Disorders of Excessive Somnolence, Parkinson Disease, Restless Legs Syndrome.
- epidemiology : Disorders of Excessive Somnolence, Parkinson Disease, Restless Legs Syndrome.
- Aged, Aged, 80 and over, Cohort Studies, Comorbidity, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Polysomnography, Reference Values.
Abstract
To investigate excessive daytime sleepiness (EDS) in patients with Parkinson's disease (PD), the reasons for which have not yet been clarified, polysomnography (PSG) and the Multiple Sleep Latency Test (MSLT) were performed in 46 patients with PD, and, in addition, PSG was performed in 30 healthy controls. Assessment included Epworth Sleepiness Score (ESS), Mini-Mental State Examination (MMSE), and Hamilton Test (HT) for depression. Fifty percent of PD patients reported EDS (ESS, 10 +/- 4.5 vs. 6.9 +/- 3.7; P = 0.01). Compared with controls, PD patients as a group had lower sleep efficiency (65 +/- 22 vs. 77 +/- 14; P = 0.03), a longer Stage 2 (73 +/- 12 vs. 67 +/- 12; P = 0.03), and a shorter rapid eye movement stage (8 +/- 8 vs. 17 +/- 8; P < 0.001). Clinical data and sleep characteristics were similar in PD with/without EDS. Of interest, patients treated with clonazepam (CLNZ) had lower EDS than those without CLNZ (ESS, 7.9 +/- 4.7 vs. 11.3 +/- 4.0; P = 0.03). These patients suffered less periodic leg movement during sleep (2.1 +/- 2.7 vs. 12.4 +/- 28; P = 0.04), which might explain the finding. No correlation was found between ESS, MSLT, and all other clinical features analyzed. In PD patients, according to the data obtained, severity of EDS does not depend on any specific clinical factor and the etiology is probably multifactorial. Paradoxically, PD patients treated with CLNZ were less sleepy than patients not treated with CLNZ.
DOI: 10.1002/mds.21002
PubMed: 16773617
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:16773617Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study.</title><author><name sortKey="Shpirer, Isaac" sort="Shpirer, Isaac" uniqKey="Shpirer I" first="Isaac" last="Shpirer">Isaac Shpirer</name><affiliation wicri:level="1"><nlm:affiliation>Sleep Laboratory, Assaf Harofeh Medical Center, Zerifin, Israel, affiliated to Sackler School of Medicine, Tel Aviv University, Israel. i_shpirer@yahoo.com</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Sleep Laboratory, Assaf Harofeh Medical Center, Zerifin, Israel, affiliated to Sackler School of Medicine, Tel Aviv University</wicri:regionArea><wicri:noRegion>Tel Aviv University</wicri:noRegion></affiliation></author><author><name sortKey="Miniovitz, Ala" sort="Miniovitz, Ala" uniqKey="Miniovitz A" first="Ala" last="Miniovitz">Ala Miniovitz</name></author><author><name sortKey="Klein, Colin" sort="Klein, Colin" uniqKey="Klein C" first="Colin" last="Klein">Colin Klein</name></author><author><name sortKey="Goldstein, Richard" sort="Goldstein, Richard" uniqKey="Goldstein R" first="Richard" last="Goldstein">Richard Goldstein</name></author><author><name sortKey="Prokhorov, Tatiana" sort="Prokhorov, Tatiana" uniqKey="Prokhorov T" first="Tatiana" last="Prokhorov">Tatiana Prokhorov</name></author><author><name sortKey="Theitler, Jack" sort="Theitler, Jack" uniqKey="Theitler J" first="Jack" last="Theitler">Jack Theitler</name></author><author><name sortKey="Pollak, Lea" sort="Pollak, Lea" uniqKey="Pollak L" first="Lea" last="Pollak">Lea Pollak</name></author><author><name sortKey="Rabey, Jose Martin" sort="Rabey, Jose Martin" uniqKey="Rabey J" first="Jose Martin" last="Rabey">Jose Martin Rabey</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.21002</idno><idno type="RBID">pubmed:16773617</idno><idno type="pmid">16773617</idno><idno type="wicri:Area/PubMed/Corpus">002B97</idno><idno type="wicri:Area/PubMed/Curation">002B97</idno><idno type="wicri:Area/PubMed/Checkpoint">002D30</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study.</title><author><name sortKey="Shpirer, Isaac" sort="Shpirer, Isaac" uniqKey="Shpirer I" first="Isaac" last="Shpirer">Isaac Shpirer</name><affiliation wicri:level="1"><nlm:affiliation>Sleep Laboratory, Assaf Harofeh Medical Center, Zerifin, Israel, affiliated to Sackler School of Medicine, Tel Aviv University, Israel. i_shpirer@yahoo.com</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Sleep Laboratory, Assaf Harofeh Medical Center, Zerifin, Israel, affiliated to Sackler School of Medicine, Tel Aviv University</wicri:regionArea><wicri:noRegion>Tel Aviv University</wicri:noRegion></affiliation></author><author><name sortKey="Miniovitz, Ala" sort="Miniovitz, Ala" uniqKey="Miniovitz A" first="Ala" last="Miniovitz">Ala Miniovitz</name></author><author><name sortKey="Klein, Colin" sort="Klein, Colin" uniqKey="Klein C" first="Colin" last="Klein">Colin Klein</name></author><author><name sortKey="Goldstein, Richard" sort="Goldstein, Richard" uniqKey="Goldstein R" first="Richard" last="Goldstein">Richard Goldstein</name></author><author><name sortKey="Prokhorov, Tatiana" sort="Prokhorov, Tatiana" uniqKey="Prokhorov T" first="Tatiana" last="Prokhorov">Tatiana Prokhorov</name></author><author><name sortKey="Theitler, Jack" sort="Theitler, Jack" uniqKey="Theitler J" first="Jack" last="Theitler">Jack Theitler</name></author><author><name sortKey="Pollak, Lea" sort="Pollak, Lea" uniqKey="Pollak L" first="Lea" last="Pollak">Lea Pollak</name></author><author><name sortKey="Rabey, Jose Martin" sort="Rabey, Jose Martin" uniqKey="Rabey J" first="Jose Martin" last="Rabey">Jose Martin Rabey</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (therapeutic use)</term><term>Benzodiazepines (therapeutic use)</term><term>Clonazepam (therapeutic use)</term><term>Cohort Studies</term><term>Comorbidity</term><term>Disorders of Excessive Somnolence (diagnosis)</term><term>Disorders of Excessive Somnolence (drug therapy)</term><term>Disorders of Excessive Somnolence (epidemiology)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Polysomnography</term><term>Reference Values</term><term>Restless Legs Syndrome (diagnosis)</term><term>Restless Legs Syndrome (drug therapy)</term><term>Restless Legs Syndrome (epidemiology)</term><term>Sleep Stages (drug effects)</term><term>Wakefulness (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzodiazepines</term><term>Clonazepam</term><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Disorders of Excessive Somnolence</term><term>Parkinson Disease</term><term>Restless Legs Syndrome</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Sleep Stages</term><term>Wakefulness</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Disorders of Excessive Somnolence</term><term>Parkinson Disease</term><term>Restless Legs Syndrome</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Disorders of Excessive Somnolence</term><term>Parkinson Disease</term><term>Restless Legs Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cohort Studies</term><term>Comorbidity</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Polysomnography</term><term>Reference Values</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To investigate excessive daytime sleepiness (EDS) in patients with Parkinson's disease (PD), the reasons for which have not yet been clarified, polysomnography (PSG) and the Multiple Sleep Latency Test (MSLT) were performed in 46 patients with PD, and, in addition, PSG was performed in 30 healthy controls. Assessment included Epworth Sleepiness Score (ESS), Mini-Mental State Examination (MMSE), and Hamilton Test (HT) for depression. Fifty percent of PD patients reported EDS (ESS, 10 +/- 4.5 vs. 6.9 +/- 3.7; P = 0.01). Compared with controls, PD patients as a group had lower sleep efficiency (65 +/- 22 vs. 77 +/- 14; P = 0.03), a longer Stage 2 (73 +/- 12 vs. 67 +/- 12; P = 0.03), and a shorter rapid eye movement stage (8 +/- 8 vs. 17 +/- 8; P < 0.001). Clinical data and sleep characteristics were similar in PD with/without EDS. Of interest, patients treated with clonazepam (CLNZ) had lower EDS than those without CLNZ (ESS, 7.9 +/- 4.7 vs. 11.3 +/- 4.0; P = 0.03). These patients suffered less periodic leg movement during sleep (2.1 +/- 2.7 vs. 12.4 +/- 28; P = 0.04), which might explain the finding. No correlation was found between ESS, MSLT, and all other clinical features analyzed. In PD patients, according to the data obtained, severity of EDS does not depend on any specific clinical factor and the etiology is probably multifactorial. Paradoxically, PD patients treated with CLNZ were less sleepy than patients not treated with CLNZ.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16773617</PMID><DateCreated><Year>2006</Year><Month>09</Month><Day>27</Day></DateCreated><DateCompleted><Year>2007</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>9</Issue><PubDate><Year>2006</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study.</ArticleTitle><Pagination><MedlinePgn>1432-8</MedlinePgn></Pagination><Abstract><AbstractText>To investigate excessive daytime sleepiness (EDS) in patients with Parkinson's disease (PD), the reasons for which have not yet been clarified, polysomnography (PSG) and the Multiple Sleep Latency Test (MSLT) were performed in 46 patients with PD, and, in addition, PSG was performed in 30 healthy controls. Assessment included Epworth Sleepiness Score (ESS), Mini-Mental State Examination (MMSE), and Hamilton Test (HT) for depression. Fifty percent of PD patients reported EDS (ESS, 10 +/- 4.5 vs. 6.9 +/- 3.7; P = 0.01). Compared with controls, PD patients as a group had lower sleep efficiency (65 +/- 22 vs. 77 +/- 14; P = 0.03), a longer Stage 2 (73 +/- 12 vs. 67 +/- 12; P = 0.03), and a shorter rapid eye movement stage (8 +/- 8 vs. 17 +/- 8; P < 0.001). Clinical data and sleep characteristics were similar in PD with/without EDS. Of interest, patients treated with clonazepam (CLNZ) had lower EDS than those without CLNZ (ESS, 7.9 +/- 4.7 vs. 11.3 +/- 4.0; P = 0.03). These patients suffered less periodic leg movement during sleep (2.1 +/- 2.7 vs. 12.4 +/- 28; P = 0.04), which might explain the finding. No correlation was found between ESS, MSLT, and all other clinical features analyzed. In PD patients, according to the data obtained, severity of EDS does not depend on any specific clinical factor and the etiology is probably multifactorial. Paradoxically, PD patients treated with CLNZ were less sleepy than patients not treated with CLNZ.</AbstractText><CopyrightInformation>(c) 2006 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shpirer</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sleep Laboratory, Assaf Harofeh Medical Center, Zerifin, Israel, affiliated to Sackler School of Medicine, Tel Aviv University, Israel. i_shpirer@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miniovitz</LastName><ForeName>Ala</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Prokhorov</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Theitler</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pollak</LastName><ForeName>Lea</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rabey</LastName><ForeName>Jose Martin</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>5PE9FDE8GB</RegistryNumber><NameOfSubstance UI="D002998">Clonazepam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2007 Jul 30;22(10):1520-1</RefSource><PMID Version="1">17486618</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2007 Jul 30;22(10):1520; author reply 1520-1</RefSource><PMID Version="1">17534962</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001569">Benzodiazepines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002998">Clonazepam</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015897">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006970">Disorders of Excessive Somnolence</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D017286">Polysomnography</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012016">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012148">Restless Legs Syndrome</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012894">Sleep Stages</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014851">Wakefulness</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21002</ArticleId><ArticleId IdType="pubmed">16773617</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Israël</li></country></list><tree><noCountry><name sortKey="Goldstein, Richard" sort="Goldstein, Richard" uniqKey="Goldstein R" first="Richard" last="Goldstein">Richard Goldstein</name><name sortKey="Klein, Colin" sort="Klein, Colin" uniqKey="Klein C" first="Colin" last="Klein">Colin Klein</name><name sortKey="Miniovitz, Ala" sort="Miniovitz, Ala" uniqKey="Miniovitz A" first="Ala" last="Miniovitz">Ala Miniovitz</name><name sortKey="Pollak, Lea" sort="Pollak, Lea" uniqKey="Pollak L" first="Lea" last="Pollak">Lea Pollak</name><name sortKey="Prokhorov, Tatiana" sort="Prokhorov, Tatiana" uniqKey="Prokhorov T" first="Tatiana" last="Prokhorov">Tatiana Prokhorov</name><name sortKey="Rabey, Jose Martin" sort="Rabey, Jose Martin" uniqKey="Rabey J" first="Jose Martin" last="Rabey">Jose Martin Rabey</name><name sortKey="Theitler, Jack" sort="Theitler, Jack" uniqKey="Theitler J" first="Jack" last="Theitler">Jack Theitler</name></noCountry><country name="Israël"><noRegion><name sortKey="Shpirer, Isaac" sort="Shpirer, Isaac" uniqKey="Shpirer I" first="Isaac" last="Shpirer">Isaac Shpirer</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D30 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002D30 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:16773617
|texte= Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:16773617" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |